Glyxambi 01
Glyxambi Tablet, Film Coated
Product Images NDC 0597-0182
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Glyxambi (NDC 0597-0182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Glyxambi 02
Glyxambi 03
This text seems to be a list of various antidiabetic drugs, with their dosages and administration frequency. Additionally, there are other medications mentioned such as Simvastatin, Warfarin, Verapamil, Ramiprl, Gemfibrozil, Hydrochlorothiazide, Torsemide, Rifampicin, and Probenecid. The text mentions various abbreviations such as Cmax, Auc, and Ave along with a geometric mean ratio (90% confidence interval). However, it is not clear what the numbers or ratios signify. Therefore, without more context, it is not possible to provide a useful description.*
Glyxambi 04
Geometric mean ratio (90% confidence interval) of various drugs, including antidiabetics, contraceptives, statins, warfarin, ramipril, digoxin, hydrochlorothiazide, and torsemide. The text includes information on the dosage, administration, and pharmacokinetic parameters of these drugs.*
Glyxambi 05
This appears to be a table showing the results of a study involving different doses of Empa and Lina medications over time. The table shows the number of participants (N) and the mean change from baseline in HbA1c levels, adjusted for baseline HbA1c, geographical region, and eGFR at baseline. It seems that there were four different doses of Empa and one dose of Lina tested, with measurements taken at various intervals up to 24 weeks.*
Glyxambi 06
This is a table showing the number of patients who had an event during a clinical trial involving the drug Empagliflozin compared to a placebo. The events are not specified in the provided text, and the subjects are divided into columns to represent subjects at risk each month.*
Glyxambi 07
This seems to be a table showing the number of patients with events (percentage) for Placebo and Empaglifiozin, across different months in 2012. It is not clear what these events are or what the significance of the numbers may be without further context.*
Glyxambi 08
Glyxambi 09
Glyxambi 10
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
